laboratory abnormalities

Related by string. * LABORATORY . Laboratory : NASA Jet Propulsion Laboratory . Jet Propulsion Laboratory . Renewable Energy Laboratory NREL . Renewable Energy Laboratory . Applied Physics Laboratory . laboratory / Abnormalities : fetal abnormalities . chromosome abnormalities . additional cytogenetic abnormalities . rhythm abnormalities . physiological abnormalities * *

Related by context. Frequent words. (Click for all words.) 76 events AEs 76 treatment emergent adverse 72 Adverse events 71 discontinuations due 69 leukopenia 69 events SAEs 68 hypocalcemia 68 hypokalemia 68 febrile neutropenia 68 hypomagnesemia 66 TYSABRI treated 66 plus methotrexate 66 thrombocytopenia 66 thromboembolic events 65 hypercalcemia 65 AEs 65 dose limiting toxicities 65 LVEF 65 myelosuppression 65 peripheral edema 65 cytogenetic response 65 infusion reactions 65 nasopharyngitis 64 arthralgia 64 NYHA class 64 P = .# 63 63 patients receiving ERBITUX 63 thromboembolism 63 virologic failure 63 Neutropenia 63 HbA1c levels 63 stomatitis 63 mg kg dose 63 renal insufficiency 63 SAEs 63 limiting toxicity 62 toxicities 62 mg BID 62 neutropenia 62 renal impairment 62 discontinuations 61 myocardial infarctions 61 asthenia 61 left ventricular dysfunction 61 RLS symptoms 61 placebo p 61 Secondary endpoints 61 composite endpoint 61 dyspnea 60 elevated liver enzymes 60 adalimumab 60 comorbid conditions 60 mg QD 60 mucositis 60 severe hypoglycemia 60 pyrexia 60 hematologic 60 fasting plasma glucose 60 lamotrigine 60 relapsing remitting 60 hyperkalemia 60 % CI #.#-#.# [006] 60 confidence interval #.#-#.# 60 fasting insulin 60 hepatic impairment 60 hypersensitivity reactions 60 hyperactivity impulsivity 60 confidence interval CI 59 CMV infection 59 neoplasm 59 vertebral fracture 59 serum concentrations 59 certolizumab pegol 59 COPAXONE R 59 p = #.# [002] 59 renal dysfunction 59 creatinine clearance 59 hepatotoxicity 59 severe renal impairment 59 active comparator 59 statistically significant p 59 antihypertensive medications 59 FOLFIRI 58 neoplasms 58 congenital malformations 58 nonsignificant 58 valacyclovir 58 angioedema 58 systemic lupus erythematosus SLE 58 asthma exacerbations 58 peginterferon alfa 2b 58 thrombotic events 58 etiologies 58 exacerbations 58 postoperative complications 58 Postoperative 58 left ventricular ejection 58 squamous 58 lactic acidosis 58 Secondary endpoints include

Back to home page